SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery
Primary Purpose
Adhesions, Colectomy
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Polylactic Acid Sheet
Sponsored by
About this trial
This is an interventional prevention trial for Adhesions focused on measuring Surgery, Colectomy, Proctocolectomy, Adhesions
Eligibility Criteria
Inclusion Criteria:
- Patient is 18 years of age or older of either gender
- Patient has primary diagnosis requiring a two-stage colectomy or procto-colectomy
- Patient or his/her legal representative has read and signed the Institutional Review Board (IRB) approved Informed Consent form before randomization.
- Patient must be able and willing to follow study procedures and instructions.
Exclusion Criteria:
- Patient is participating in another clinical study which may influence adhesion formation.
- Patient has had barriers, solutions, or anti-adhesive therapy, other than SurgiWrapTM, as planned at randomization, placed in the abdomen at the time of the initial surgery
- Patient who, at the initial surgery, had administration of irrigants containing corticosteroids, heparin, salicylates, nonsteroidal anti-inflammatory drugs, or dextran 70
- Patient has one or more medical condition(s), including severe renal, hepatic, hematologic, neurologic, or immune disease that, in the opinion of the Investigator, would make the patient an inappropriate candidate for this study.
- Patient is taking chronic (i.e., > 2 weeks) therapeutic doses of medications known to affect healing such as nonsteroidal anti-inflammatory drugs. Prophylactic aspirin (less than or equal to 325 mg once daily) for cardiovascular indications will be permitted in patients.
- Patient has an infection in the intra-abdominal or pelvic area.
Sites / Locations
- University of Southern California Norris Cancer Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Active Comparator
Arm Label
A
B
Arm Description
Colorectal Surgery without use of SurgiWrapTM
Colorectal Surgery with use of SurgiWrapTM film secured in two study areas: the posterior pelvic rim and directly below the abdominal incision
Outcomes
Primary Outcome Measures
Assess the efficacy of SurgiWrapTM in the prevention/reduction of Grade 2 or higher soft tissue attachments under the abdominal incision made during colorectal surgery
Secondary Outcome Measures
Clinical and radiographic evidence of bowel obstruction
The incidence and extent of soft tissue attachments under the abdominal incision and on the pelvic floor after colorectal surgery
Full Information
NCT ID
NCT00531739
First Posted
September 18, 2007
Last Updated
October 5, 2010
Sponsor
Cytori Therapeutics
1. Study Identification
Unique Protocol Identification Number
NCT00531739
Brief Title
SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery
Official Title
Phase 4 Evaluation of SurgiWrapTM to Minimize Soft Tissue Attachment & Reduce the Incidence of Early Post-Operative Bowel Obstruction in Colorectal Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
October 2010
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Cytori Therapeutics
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine if the use of SurgiWrapTM: (1) prevents/lowers the incidence of Grade 2 or higher soft tissue attachments under the incision made during abdominal surgery, (2) reduces post-operative bowel obstruction.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adhesions, Colectomy
Keywords
Surgery, Colectomy, Proctocolectomy, Adhesions
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
No Intervention
Arm Description
Colorectal Surgery without use of SurgiWrapTM
Arm Title
B
Arm Type
Active Comparator
Arm Description
Colorectal Surgery with use of SurgiWrapTM film secured in two study areas: the posterior pelvic rim and directly below the abdominal incision
Intervention Type
Other
Intervention Name(s)
Polylactic Acid Sheet
Other Intervention Name(s)
SurgiWrapTM
Intervention Description
SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
Primary Outcome Measure Information:
Title
Assess the efficacy of SurgiWrapTM in the prevention/reduction of Grade 2 or higher soft tissue attachments under the abdominal incision made during colorectal surgery
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Clinical and radiographic evidence of bowel obstruction
Time Frame
5 to 30 days
Title
The incidence and extent of soft tissue attachments under the abdominal incision and on the pelvic floor after colorectal surgery
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is 18 years of age or older of either gender
Patient has primary diagnosis requiring a two-stage colectomy or procto-colectomy
Patient or his/her legal representative has read and signed the Institutional Review Board (IRB) approved Informed Consent form before randomization.
Patient must be able and willing to follow study procedures and instructions.
Exclusion Criteria:
Patient is participating in another clinical study which may influence adhesion formation.
Patient has had barriers, solutions, or anti-adhesive therapy, other than SurgiWrapTM, as planned at randomization, placed in the abdomen at the time of the initial surgery
Patient who, at the initial surgery, had administration of irrigants containing corticosteroids, heparin, salicylates, nonsteroidal anti-inflammatory drugs, or dextran 70
Patient has one or more medical condition(s), including severe renal, hepatic, hematologic, neurologic, or immune disease that, in the opinion of the Investigator, would make the patient an inappropriate candidate for this study.
Patient is taking chronic (i.e., > 2 weeks) therapeutic doses of medications known to affect healing such as nonsteroidal anti-inflammatory drugs. Prophylactic aspirin (less than or equal to 325 mg once daily) for cardiovascular indications will be permitted in patients.
Patient has an infection in the intra-abdominal or pelvic area.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexander M Milstein, MD
Organizational Affiliation
Cytori Therapeutics
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Robert Beard, MD
Organizational Affiliation
University of Southern California
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Southern California Norris Cancer Hospital
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
12. IPD Sharing Statement
Learn more about this trial
SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery
We'll reach out to this number within 24 hrs